Medplus Health Services Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Store build-out dominates the P&L: 995 net new stores in 12 months, with 49% of the fleet now under two years old, compressing reported margins even as the underlying unit economics stay intact.
• A bold private-label reset is underway: The old MHS/Wynclark brands are being merged into a single "MedPlus" label sold at a 50–80% discount, sacrificing per-unit margin to drive customer acquisition and lift the private-label mix from 8% toward 20%.
• Revenue per store is declining, by design: The metric fell to 12.8 this quarter, driven by the heavy mix of immature stores and a seasonal demand lull; management frames this as a temporary ramp-up cost, not a structural problem.
• The margin bridge is visible but back-end loaded: A mature two-year store earns 10% store-level EBITDA, and with scale benefits plus automation, the consolidated entity targets a 5%+ EBITDA margin, up from current levels.
• What to watch next quarter: The pace of the MedPlus brand rollout beyond Telangana, the trajectory of the 14.5% private-label mix toward 20%, and whether the 800–1,000 store addition target for the year stays on track without straining the balance sheet.

Store Network & Maturity

• Aggressive expansion, concentrated geography: 168 stores opened in Q1, with West Bengal (53) and Karnataka (32) leading; 53% of openings were in Tier-2 cities and beyond, where rent and manpower costs are lower and private-label acceptance is higher.
• Immaturity is the dominant margin drag: 49% of stores are less than two years old, up from 45% a year ago, and all of them are still in ramp-up and weigh on operating EBITDA.
• Young stores ramp fast: Stores opened between July and December 2022 achieved cohort-level breakeven in just four months, with 58% breaking even within six months.
• Closures are small and mostly relocations: 15 stores closed in Q1, average age over seven years; 8 were relocations and the rest lost to lease renewals or visibility issues, so management does not view this as lost revenue.
• Tier-2 economics are structurally better: Top line runs 10–15% below metro stores, but lower rent and manpower costs plus a richer private-label mix push store-level EBITDA margin slightly higher.

Private-Label Transformation

• A single brand replaces two: The legacy MHS and Wynclark labels are being merged into one "MedPlus" brand, launched June 17 in Hyderabad and Telangana with 433 SKUs, expanding to ~800 over the next three months.
• Pricing is the acquisition engine: The new MedPlus brand is sold at a 50–80% discount to branded equivalents, a deliberate choice to bring in new customers and grow top-line; the old private label was sold at full price.
• Mix gain offsets per-unit margin dilution: On an absolute margin basis, the new label earns less than the old one but far more than branded products; because the overall private-label mix has risen from 8% to 14.5%, total margins are "more or less in line" with earlier levels.
• Manufacturing is outsourced to top-tier partners: Around 10 manufacturers have been shortlisted, all of whom already produce for the country's largest pharma brands; management declined to name them.
• The subscription plan locks in loyalty: The MedPlus Advantage plan, priced at ₹499/year (launched at ₹49), gives members access to the discounted MedPlus range; the plan was recently tweaked to allow add-on family members and a ₹150 renewal discount.
• MRP and discount are both in the company's control: Within government guidelines, management can adjust both the listed price and the 50–80% discount, with the stated goal of maximizing customer acquisition before optimizing pricing.

Gangadi: "Our scale allows us to actually give a price which no one else can match. At the same time, we also have a size and scale and capability which allows us to actually make or at least have these drugs contract manufactured at the best facilities across the country and give them at a price at which no one else can match."

Revenue & Margin Dynamics

• Revenue per store is falling, temporarily: The metric dropped from 13.2–13.3 in the first nine months of FY23 to 12.8 this quarter, attributed to the over-50% mix of sub-two-year stores and a seasonal dip in infections during an extended summer.
• Gross margin compressed 130 bps QoQ: The drivers were a 0.4% seasonal discount increase and a reduction in private-label sales, as Q1 typically sees fewer infectious diseases and therefore lower OTC and antibiotic volumes.
• The mature-store margin model is the north star: A two-year store earns 10% EBITDA at store level; after deducting 2% corporate overhead and 3% warehousing cost, the consolidated entity would report 5% EBITDA margin if the entire network were mature.
• Scale benefits are still to come: As revenue moves from ~₹4,500 crore toward ₹6,000 crore, warehousing and corporate costs are not expected to keep pace, and together with private-label expansion, this should push consolidated EBITDA margin beyond 5%.
• Warehouses are nearly full: Most facilities are utilized almost fully; expansion into new states (Kerala, Chhattisgarh, Madhya Pradesh) will require new warehouses once store counts reach 20–50 per state, but no new warehouses are planned this year.

Gangadi: "As of now, yes, but as we go forward with scale benefit and with private label and everything else, we expect this will continue to improve."

Diagnostics: Small Base, Early Trajectory

• Revenue is scaling from a low base: Diagnostics revenue grew to ₹13.9 crore from ₹3.2 crore, driven primarily by new center launches in Hyderabad; the operating EBITDA loss narrowed to ₹4.6 crore from ₹5.2 crore.
• Membership crossed a milestone: Active membership surpassed 1 lakh, covering 180,000 lives, with a target of 250,000 underlying lives.
• Center-level breakeven is in sight: Centers turn EBITDA-neutral from the eighth month onward; Q1 was seasonally weak but the trajectory remains on track, and a 12th center will be added in Hyderabad.

Operations & Automation

• In-house automation is live and expanding: Half of all oral tablets and capsules in the Hyderabad warehouse are now picked by an automatic picking machine developed internally; full automation of the Chennai warehouse is planned over the next quarter or so.
• The savings are material: Full automation could reduce warehousing cost from 3% of revenue to 2.0–2.25%, saving 0.75–1.0% on overall cost.

Gangadi: "we will also be able to save in the range of let's say 0.75% to 1% on the overall cost. So, I would say a 3% cost would probably end up coming somewhere to 2% to 2.25%."

Guidance & Commitments

Key Metrics